We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Fluxergy Introduces First-of-Its-Kind Multi-Modal Laboratory Platform That Diagnoses COVID-19 On-Site in 60 Minutes

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021
Print article
Image: Fluxergy COVID-19 Diagnostic Platform (Photo courtesy of Fluxergy)
Image: Fluxergy COVID-19 Diagnostic Platform (Photo courtesy of Fluxergy)

Fluxergy (Irvine, CA, USA) introduced the first-of-its-kind multi-modal laboratory platform that diagnoses COVID-19 on-site in 60 minutes at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest laboratory medicine tradeshow.

Fluxergy’s portable, highly sophisticated and easy to use sample-to-answer POC platform enables clinicians to cost-effectively conduct a wide range of multiplex and multimodal in vitro diagnostic tests (different types of tests all at once, up to 30 targets). The company’s portable testing platform is based on three core elements: the single-use consumable Fluxergy Card, the Fluxergy Analyzer, and its user interface Fluxergy Works. The Fluxergy Analyzer and the single-use consumable Fluxergy Cards (lab-on-chip) use proprietary printed circuit board (PCB) manufacturing and microfluidics technologies. Leveraging Fluxergy Works Software, as many as 256 Fluxergy Analyzers can be managed with one local server and linked to the Cloud to provide powerful access to help manage patient data.

The Fluxergy Analyzer system has been shown to accurately identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by the company and in follow-up validation tests with patient samples. One of the advantages of the Fluxergy system is that it is lightweight and portable – the Fluxergy Analyzer is about the size of a small desktop personal computer – which makes it applicable in a variety of clinical settings. Importantly, the Fluxergy system also does not require the SARS-Cov-2 RNA to be purified before the test can be performed. Samples are placed directly on a disposable sample-to-answer Fluxergy test card, which uses printed circuit board technology and microfluidics to automate various sample processing steps.

Advanced rapid point-of-care PCR tests for COVID-19 like the Fluxergy Analyzer system may have the potential to save significant time compared to standard lab tests that must be shipped to centralized laboratories for processing. Fluxergy’s on-site sample-to-answer test for COVID-19 requires a very small sample, typically a nasal swab. This swab is mixed with a reagent solution, loaded onto the Fluxergy card and inserted into the Fluxergy Analyzer in a convenient two-step procedure.

Related Links:
Fluxergy 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay

Print article
ADLM

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.